The Institute for Clinical and Economic Review has released a report on lecanemab, an anti-amyloid monoclonal antibody approved by the FDA for the treatment of Alzheimer’s disease. The report found that while lecanemab showed a statistically significant 27% slowing of cognitive decline compared to placebo, there are concerns about the potential harm from amyloid-related imaging abnormalities. The report also found that lecanemab’s annual price of $26,500 exceeds commonly used cost-effectiveness thresholds, and recommended efforts to achieve affordability and access. The report calls for all stakeholders to address health inequities in introducing new treatments for Alzheimer’s disease, and for manufacturers to follow the example of the lecanemab manufacturer in sharing transparent pricing justifications and releasing all patient-level data.
🌟 Embracing technology for elderly care is essential in enhancing health and independence. Discover how smart home technologies, wearable devices, and telehealth services are shifting elderly care. Let’s create a supportive environment for our ageing population.
#SyenzaNews #ElderlyCare #AIInHealthcare #HealthTech #Telehealth #WearableTech #SmartHome 🌐
Learn more about the latest innovations in elderly care and how they can improve the quality of life for older adults.
🌍📈 The elderly population in Sub-Saharan Africa is set to triple by 2050, presenting unique healthcare challenges. Our latest article explores the current policy environment, healthcare needs, and future directions for effective policymaking. Let’s ensure our ageing population receives the care and support they deserve. Read more on our website! #SyenzaNews #Healthcare #AgingPopulation #SubSaharanAfrica #PolicyResearch 🌟
🔍 Explore the latest insights on dementia risk factors in the UK! Unveiling trends, disparities, and strategies for effective prevention. Let’s work towards a healthier future together!
#SyenzaNews #HealthcareUK #DementiaResearch #PreventDementia #ResearchInsights 🧠
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
